Jeremy Meinen - Relief Therapeutics Chief Admin
| RLF Stock | CHF 5.04 0.04 0.80% |
Insider
Jeremy Meinen is Chief Admin of Relief Therapeutics Holding
| Age | 32 |
| Phone | 41 44 723 59 59 |
| Web | https://www.relieftherapeutics.com |
Relief Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1217) % which means that it has lost $0.1217 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3257) %, meaning that it generated substantial loss on money invested by shareholders. Relief Therapeutics' management efficiency ratios could be used to measure how well Relief Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jack MBA | Relief Therapeutics Holding | 67 | |
| Markus Nikles | Meyer Burger Tech | 51 | |
| Molly Cogan | NRX Pharmaceuticals | N/A | |
| Seth Voorhees | NRX Pharmaceuticals | 63 | |
| Philipp Frech | Evolva Holding SA | N/A | |
| Oliver MBA | Evolva Holding SA | 54 | |
| Gerhard Lobmaier | Evolva Holding SA | 54 | |
| Kaspar Mueller | Evolva Holding SA | 60 | |
| Prof Javitt | NRX Pharmaceuticals | N/A | |
| Philip Lavin | NRX Pharmaceuticals | 77 | |
| Robert MIM | NRX Pharmaceuticals | 58 | |
| Thomas CFA | Evolva Holding SA | N/A | |
| Drew CroninFine | Relief Therapeutics Holding | N/A | |
| DPhil MBA | Relief Therapeutics Holding | 60 | |
| Serene MPH | Relief Therapeutics Holding | N/A | |
| David McCullough | Relief Therapeutics Holding | N/A | |
| Astrid Schafer | Evolva Holding SA | 50 | |
| Michael Kunz | NRX Pharmaceuticals | 59 | |
| Dorian Bevec | Relief Therapeutics Holding | 65 | |
| Gunter Erfurt | Meyer Burger Tech | 50 | |
| Katja Tavernaro | Meyer Burger Tech | 46 | |
Management Performance
| Return On Equity | -0.33 | |||
| Return On Asset | -0.12 |
Relief Therapeutics Leadership Team
Elected by the shareholders, the Relief Therapeutics' board of directors comprises two types of representatives: Relief Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Relief. The board's role is to monitor Relief Therapeutics' management team and ensure that shareholders' interests are well served. Relief Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Relief Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeremy CPA, CFO Officer | ||
| David McCullough, Sr Access | ||
| DPhil MBA, Chief Officer | ||
| Jeremy Meinen, Chief Admin | ||
| Dorian Bevec, Chief Lifescience | ||
| Drew CroninFine, Exec Marketing | ||
| Christopher Wick, Sr Sales | ||
| Paolo Galfetti, COO Director | ||
| Marco Marotta, Chief Officer | ||
| Jack Weinstein, Treasurer CFO | ||
| Anthony Kim, Sr Operations | ||
| Jack MBA, Chief Officer | ||
| Serene MPH, VP Medicine |
Relief Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Relief Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.33 | |||
| Return On Asset | -0.12 | |||
| Operating Margin | (5.96) % | |||
| Current Valuation | 95.8 M | |||
| Shares Outstanding | 4.39 B | |||
| Shares Owned By Insiders | 3.68 % | |||
| Shares Owned By Institutions | 22.16 % | |||
| Price To Earning | 277.00 X | |||
| Price To Book | 0.76 X | |||
| Price To Sales | 18.81 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Relief Stock Analysis
When running Relief Therapeutics' price analysis, check to measure Relief Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relief Therapeutics is operating at the current time. Most of Relief Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relief Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relief Therapeutics' price. Additionally, you may evaluate how the addition of Relief Therapeutics to your portfolios can decrease your overall portfolio volatility.